009089/EU XXV. GP
Eingelangt am 16/01/14

COUNCIL OF THE EUROPEAN UNION

Brussels, 16 January 2014 (OR. en)

5400/14 ADD 1

MI 45
CHIMIE 4
ENV 40
COMPET 25
ENT 12

COVER NOTE

From:	European Commission
date of receipt:	14 January 2014
To:	General Secretariat of the Council
Subject:	ANNEX to the COMMISSION REGULATION (EU) No …/.. of XXX amending, for the purposes of introducing hazard and precautionary statements in the Croatian language and its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures

Delegations will find attached annex to document D027409/04 ANNEX.

Encl.: D027409/04 ANNEX

EN

ANNEX 1 to 3

ANNEX 1

In Part 1 of Annex III, Table 1.1 is amended as follows:

(1) In code H229, the following is inserted after the entry corresponding to GA:

	'HR	Spremnik pod tlakom: može se rasprsnuti ako se grije.'

(2) In code H230, the following is inserted after the entry corresponding to GA:

	'HR	Može eksplozivno reagirati i bez prisustva zraka.'

(3) In code H231, the following is inserted after the entry corresponding to GA:

	'HR	Može eksplozivno reagirati i bez prisustva zraka na povišenom tlaku i/ili temperaturi.'

ANNEX 2

Part 2 to Annex IV is amended as follows:

(1) Table 1.2 is amended as follows:

(a) In code P210, the following is inserted after the entry corresponding to GA:

	'HR	Čuvati odvojeno od topline, vrućih površina, iskri, otvorenih plamena i ostalih izvora paljenja. Ne pušiti. '

(b) In code P223: The following is inserted after the entry corresponding to GA:

	'HR	Spriječiti dodir s vodom. '

(c) In code P244, the following is inserted after the entry corresponding to GA:

	'HR	Spriječiti dodir ventila i spojnica s uljem i masti. '

(d) In code P251, the following is inserted after the entry corresponding to GA:

	'HR	Ne bušiti, niti paliti čak niti nakon uporabe. '

(e) In code P284, the following is inserted after the entry corresponding to GA:

	'HR	[U slučaju nedovoljne ventilacije] nositi sredstva za zaštitu dišnog sustava. '

Table 1.3 is amended as follows:

(a) In code P310, the following is inserted after the entry corresponding to GA:

	'HR	Odmah nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/...'

(b) In code P 311, the following is inserted after the entry corresponding to GA:

	'HR	Nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/...'

(c) In code P312: The following is inserted after the entry corresponding to GA:

	'HR	U slučaju zdravstvenih tegoba nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/...'

(d) In code P340, the following is inserted after the entry corresponding to GA:

	'HR	Premjestiti osobu na svježi zrak i postaviti ju u položaj koji olakšava disanje. '

(e) In code P352, the following is inserted after the entry corresponding to GA:

	'HR	Oprati velikom količinom vode/...'

(f) In code P361, the following is inserted after the entry corresponding to GA:

	'HR	Odmah skinuti svu zagađenu odjeću. '

(g) In code P362, the following is inserted after the entry corresponding to GA:

	'HR	Skinuti zagađenu odjeću. '

(h) In code P364, the following is inserted after the entry corresponding to GA:

	'HR	I oprati je prije ponovne uporabe. '

(i) In code P378, the following is inserted after the entry GA:

	'HR	Za gašenje rabiti …'

(j) In combined codes P301+P310, the following is inserted after the entry corresponding to GA:

	'HR	AKO SE PROGUTA: odmah nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…'

(k) In combined codes P301+P312, the following is inserted after the entry corresponding to GA:

	'HR	AKO SE PROGUTA: u slučaju zdravstvenih tegoba nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/...'

(l) In combined codes P302+P352, the following is inserted after the entry corresponding to GA:

	'HR	U SLUČAJU DODIRA S KOŽOM: oprati velikom količinom vode/...'

(m) In combined codes P303+P361+P353, the following is inserted after the entry corresponding to GA:

	'HR	U SLUČAJU DODIRA S KOŽOM (ili kosom): odmah skinuti svu zagađenu odjeću. Isprati kožu vodom/tuširanjem.'

(n) In combined codes P304+P340, the following is inserted after the entry corresponding to GA:

	'HR	AKO SE UDIŠE: premjestiti osobu na svježi zrak i postaviti ju u položaj koji olakšava disanje. '

(o) Combined Codes P308+P311, the following is inserted after the entry corresponding to GA:

	'HR	U SLUČAJU izloženosti ili sumnje na izloženost: nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/...'

(p) In combined codes P342+P311, the following is inserted after the entry corresponding to GA:

	'HR	Pri otežanom disanju: nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/...'

(q) In combined codes P361+P364, the following is inserted after the entry corresponding to GA:

	'HR	Odmah skinuti svu zagađenu odjeću i oprati je prije ponovne uporabe. '

(r) In combined codes P362+P364, the following is inserted after the entry corresponding to GA:

	'HR	Skinuti zagađenu odjeću i oprati je prije ponovne uporabe. '

(s) In combined codes P370+P378, the following is inserted after the entry corresponding to GA:

	'HR	U slučaju požara: za gašenje rabiti …'

ANNEX 3

Part 3 of Annex VI is amended as follows:

(1) Table 3.1 is amended as follows:

(a) The entry corresponding to index number 015-188-00-X is deleted.

(b) The entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5, 605-008-00-3 and 616-035-00-5 are replaced by the following corresponding entries:

'006-086-00-6	**fenoxycarb (ISO); ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate**	**276-696-7**	**72490-01-8**	**Carc. 2** **Aquatic Acute 1** **Aquatic Chronic 1**	**H351** **H400** **H410**	**GHS08** **GHS09** **Wng**	**H351** **H410**		**M = 1** **M = 10000**	
015-154-00-4	**ethephon; 2-chloroethylphosphonic acid**	**240-718-3**	**16672-87-0**	**Acute Tox. 3** **Acute Tox. 4** **Acute Tox. 4** **Skin Corr. 1C** **Aquatic Chronic 2**	**H311** **H332** **H302** **H314** **H411**	**GHS06** **GHS05** **GHS09** **Dgr**	**H311** **H332** **H302** **H314** **H411**	**EUH071**		
015-192-00-1	**tetrakis(2,6-dimethylphenyl)-*m*-phenylene biphosphate**	**432-770-2**	**139189-30-3**	**Skin Sens. 1**	**H317**	**GHS07** **Wng**	**H317**			
601-023-00-4	**ethylbenzene**	**202-849-4**	**100-41-4**	**Flam. Liq. 2** **Acute Tox. 4*** **STOT RE 2**	**H225** **H332** **H373 (hearing organs)**	**GHS02** **GHS07** **GHS08** **Dgr**	**H225** **H332** **H373 (hearing organs)**			

				Asp. Tox. 1	H304		H304			
601-026-00-0	styrene	202-851-5	100-42-5	Flam. Liq. 3 Repr. 2 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2	H226 H361d H332 H372 (hearing organs) H315 H319	GHS02 GHS08 GHS07 Dgr	H226 H361d H332 H372 (hearing organs) H315 H319		*	D
603-061-00-7	tetrahydro-2-furylmethanol; tetrahydrofurfuryl alcohol	202-625-6	97-99-4	Repr. 1B Eye Irrit. 2	H360Df H319	GHS08 GHS07 Dgr	H360Df H319			
605-001-00-5	formaldehyde …%	200-001-8	50-00-0	Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* Skin Corr. 1B Skin Sens. 1	H350 H341 H301 H311 H331 H314 H317	GHS08 GHS06 GHS05 Dgr	H350 H341 H301 H311 H331 H314 H317		* Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 5 % ≤ C < 25 % STOT SE 3; H335: C ≥ 5 % Skin Sens. 1; H317: C ≥ 0,2 %	B, D
605-008-00-3	acrolein; prop-2-enal; acrylaldehyde	203-453-4	107-02-8	Flam. Liq. 2 Acute Tox. 1 Acute Tox. 2	H225 H330 H300	GHS02 GHS06 GHS05	H225 H330 H300	EUH071	Skin Corr. 1B; H314: C ≥ 0,1 %	D

				Acute Tox. 3 **Skin Corr. 1B** **Aquatic Acute 1** **Aquatic Chronic 1**	**H311** **H314** **H400** **H410**	**GHS09** **Dgr**	**H311** **H314** **H410**		**M = 100** **M = 1**	
616-035-00-5	**cymoxanil (ISO);** **2-cyano-*N*-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide**	**261-043-0**	**57966-95-7**	**Repr. 2** **Acute Tox. 4** **STOT RE 2** **Skin Sens. 1** **Aquatic Acute 1** **Aquatic Chronic 1**	**H361fd** **H302** **H373 (blood, thymus)** **H317** **H400** **H410**	**GHS08** **GHS07** **GHS09** **Wng**	**H361fd** **H302** **H373 (blood, thymus)** **H317** **H410**		**M = 1** **M = 1'**	

(c) The following entries are inserted in accordance with the order of the entries set out in Table 3.1:

'050-028-00-2	**2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate**	**260-829-0**	**57583-35-4**	**Repr. 2** **Acute Tox. 4** **STOT RE 1** **Skin Sens. 1A**	**H361d** **H302** **H372 (nervous system, immune system)** **H317**	**GHS08** **GHS07** **Dgr**	**H361d** **H302** **H372 (nervous system, immune system)** **H317**			
050-029-00-8	**dimethyltin dichloride**	**212-039-2**	**753-73-1**	**Repr. 2** **Acute Tox. 2** **Acute Tox. 3** **Acute Tox. 3** **STOT RE 1** **Skin Corr. 1B**	**H361d** **H330** **H301** **H311** **H372 (nervous system, immune system)** **H314**	**GHS08** **GHS06** **GHS05** **Dgr**	**H361d** **H330** **H301** **H311** **H372 (nervous system, immune system)** **H314**	**EUH071**		
601-088-00-9	**4-vinylcyclohexene**	**202-848-9**	**100-40-3**	**Carc. 2**	**H351**	**GHS08** **Wng**	**H351**			
601-089-00-4	**muscalure; cis-tricos-9-ene**	**248-505-7**	**27519-02-4**	**Skin Sens. 1B**	**H317**	**GHS07** **Wng**	**H317**			
604-090-00-8	**4-tert-butylphenol**	**202-679-0**	**98-54-4**	**Repr. 2** **Skin Irrit. 2** **Eye Dam. 1**	**H361f** **H315** **H318**	**GHS08** **GHS05** **Dgr**	**H361f** **H315** **H318**			

604-091-00-3	**etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether**	**407-980-2**	**80844-07-1**	**Lact.** **Aquatic Acute 1** **Aquatic Chronic 1**	**H362** **H400** **H410**	**GHS09** **Wng**	**H362** **H410**		**M = 100** **M = 1000**	
606-146-00-7	**tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one**	**-**	**87820-88-0**	**Carc. 2** **Acute Tox. 4** **Aquatic Chronic 2**	**H351** **H302** **H411**	**GHS08** **GHS07** **GHS09** **Wng**	**H351** **H302** **H411**			
606-147-00-2	**cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2*H*-thiopyran-3-yl)cyclohex-2-en-1-one**	**405-230-9**	**101205-02-1**	**Repr. 2**	**H361d**	**GHS08** **Wng**	**H361d**			
607-705-00-8	**benzoic acid**	**200-618-2**	**65-85-0**	**STOT RE 1** **Skin Irrit. 2** **Eye Dam. 1**	**H372** **(lungs)** **(inhalation)** **H315** **H318**	**GHS08** **GHS05** **Dgr**	**H372** **(lungs)** **(inhalation)** **H315** **H318**			
607-706-00-3	**methyl 2,5-dichlorobenzoate**	**220-815-7**	**2905-69-3**	**Acute Tox. 4** **STOT SE 3** **Aquatic Chronic 2**	**H302** **H336** **H411**	**GHS07** **GHS09** **Wng**	**H302** **H336** **H411**			
612-287-00-5	**fluazinam (ISO) ; 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine**	**-**	**79622-59-6**	**Repr. 2** **Acute Tox. 4** **Eye Dam. 1** **Skin Sens. 1A** **Aquatic Acute 1** **Aquatic Chronic 1**	**H361d** **H332** **H318** **H317** **H400** **H410**	**GHS08** **GHS07** **GHS05** **GHS09** **Dgr**	**H361d** **H332** **H318** **H317** **H410**		**M = 10** **M = 10**	

613-317-00-X	**penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole**	**266-275-6**	**66246-88-6**	**Repr. 2** **Acute Tox. 4** **Aquatic Acute 1** **Aquatic Chronic 1**	**H361d** **H302** **H400** **H410**	**GHS08** **GHS07** **GHS09** **Wng**	**H361d** **H302** **H410**		**M = 1** **M = 1**	
613-318-00-5	**fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate**	**-**	**473798-59-3**	**Aquatic Chronic 2**	**H411**	**GHS09**	**H411**			
616-212-00-7	**3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate**	**259-627-5**	**55406-53-6**	**Acute Tox. 3** **Acute Tox. 4** **STOT RE 1** **Eye Dam. 1** **Skin Sens. 1** **Aquatic Acute 1** **Aquatic Chronic 1**	**H331** **H302** **H372 (larynx)** **H318** **H317** **H400** **H410**	**GHS06** **GHS08** **GHS05** **GHS09** **Dgr**	**H331** **H302** **H372 (larynx)** **H318** **H317** **H410**		**M = 10** **M = 1'**	

(2) Table 3.2 is amended as follows:

(a) The entry corresponding to index number 015-188-00-X is deleted.

(b) The entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5 and 616-035-00-5 are replaced by the following corresponding entries:

'006-086-00-6	**fenoxycarb (ISO); (ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate**	**276-696-7**	**72490-01-8**	**Carc. Cat. 3; R40** **N; R50-53**	**Xn; N** **R: 40-50/53**	**N; R50-53: C ≥ 25 %**	

					S: (2-)22-36/37-60-61	N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %	
015-154-00-4	ethephon; 2-chloroethylphosphonic acid	240-718-3	16672-87-0	C; R34 Xn; R20/21/22 N; R51-53	C; N R: 20/21/22-34-51/53 S: (1/2-)26-36/37/39-45-61	Xi; R37: 5 % ≤ C < 10 %	
015-192-00-1	tetrakis(2,6-dimethylphenyl)-*m*-phenylene biphosphate	432-770-2	139189-30-3	R43	Xi R: 43 S: (2-)24-37		
601-023-00-4	ethylbenzene	202-849-4	100-41-4	F; R11 Xn; R20-48/20-65	F; Xn R: 11-20-48/20-65 S: (2-)16-24/25-29-62		
601-026-00-0	styrene	202-851-5	100-42-5	Repr. Cat. 3; R63 Xn; R20-48/20 Xi; R36/38 R10	Xn R: 10-20-36/38-48/20-63 S: (2-)23-36/37-46	Xn; R20: C ≥ 12,5 % Xi; R36/38: C ≥ 12,5 %	D
603-061-00-7	tetrahydro-2-furylmethanol; tetrahydrofurfuryl alcohol	202-625-6	97-99-4	Repr. Cat. 2; R61 Repr. Cat. 3; R62 Xi; R36	T R: 36-61-62 S: 45-53	Xi; R36: C ≥ 10 %	
605-001-00-5	formaldehyde …%	200-001-8	50-00-0	Carc. Cat. 2; R45 Muta. Cat. 3; R68 T; R23/24/25 C; R34 R43	T R: 23/24/25-34-43-45-68 S: 45-53	T; R23/24/25: C ≥ 25 % Xn; R20/21/22: 5 % ≤ C < 25 % C; R34: C ≥ 25 %	B, D

						Xi; R36/37/38: 5 % ≤ C < 25 % **R43: C ≥ 0,2 %**	
616-035-00-5	**cymoxanil (ISO);** **2-cyano-*N*-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide**	**261-043-0**	**57966-95-7**	**Repr. Cat. 3; R62-63** **Xn; R22-48/22** **R43** **N; R50-53**	**Xn; N** **R: 22-43-48/22-62-63-50/53** **S: (2-)36/37-46-60-61**	**N; R50-53: C ≥ 25 %** **N; R51-53: 2,5 % ≤ C < 25 %** **R52-53: 0,25 % ≤ C < 2,5 %'**	

(c) The following entries are inserted in accordance with the order of the entries set out in Table 3.2:

'050-028-00-2	**2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate**	**260-829-0**	**57583-35-4**	**Repr. Cat. 3; R63** **T; R48/25** **Xn; R22** **R43**	**T** **R: 22-43-48/25-63** **S: (1/2-)36/37-45**		
050-029-00-8	**dimethyltin dichloride**	**212-039-2**	**753-73-1**	**Repr. Cat. 3; R63** **T+; R26** **T; R24/25-48/25** **C; R34**	**T+** **R: 24/25-26-34-48/25-63** **S: (1/2-)26-28-36/37/39-45-63**		
601-088-00-9	**4-vinylcyclohexene**	**202-848-9**	**100-40-3**	**Carc. Cat. 3; R40**	**Xn** **R: 40** **S: (2-)36/37**		
601-089-00-4	**muscalure; cis-tricos-9-ene**	**248-505-7**	**27519-02-4**	**R43**	**Xi** **R: 43** **S: (2-)24-37**		
604-090-00-8	**4-tert-butylphenol**	**202-679-0**	**98-54-4**	**Repr. Cat. 3; R62** **Xi; R38-41**	**Xn** **R: 38-41-62** **S: (2-)26-36/37/39-46**		

604-091-00-3	**etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether**	**407-980-2**	**80844-07-1**	**R64** **N; R50-53**	**N** **R: 50/53-64** **S: 60-61**	**N; R50-53: C ≥ 0,25 %** **N; R51-53: 0,025 % ≤ C < 0,25 %** **R52-53: 0,0025 % ≤ C < 0,025 %**	
606-146-00-7	**tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one**	**–**	**87820-88-0**	**Carc. Cat. 3; R40** **Xn; R22** **N; R51-53**	**Xn; N** **R: 22-40-51/53** **S: (2-)36/37-60-61**	**N; R51-53: C ≥ 25 %** **R52-53: 2,5 % ≤ C < 25 %**	
606-147-00-2	**cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one**	**405-230-9**	**101205-02-1**	**F; R11** **Repr. Cat. 3; R63**	**F; Xn** **R: 11-63** **S: (2-)16-36/37-46**		
607-705-00-8	**benzoic acid**	**200-618-2**	**65-85-0**	**T; R48/23** **Xi; R38-41**	**T** **R: 38-41-48/23** **S: (1/2-)26-39-45-63**		
607-706-00-3	**methyl 2,5-dichlorobenzoate**	**220-815-7**	**2905-69-3**	**Xn; R22** **N; R51-53**	**Xn; N** **R: 22-51/53** **S: (2-) 46-61**		
612-287-00-5	**fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine**	**-**	**79622-59-6**	**Repr. Cat. 3; R63** **Xn; R20** **Xi; R41** **R43** **N; R50-53**	**Xn; N** **R: 20-41-43-50/53-63** **S: (2-)26-36/37/39-46-60-61**	**N; R50-53: C ≥ 2,5 %** **N; R51-53: 0,25 % ≤ C < 2,5 %** **R52-53: 0,025 % ≤ C < 0,25 %**	
613-317-00-X	**penconazole (ISO); 1-[2-(2,4-**	**266-275-6**	**66246-88-6**	**Repr. Cat. 3; R63**	**Xn; N**	**N; R50-53: C ≥**	

	dichlorophenyl)pentyl]-1H-1,2,4-triazole			**Xn; R22** **N; R50-53**	**R: 22-50/53-63** **S: (2-) 36/37-46-60-61**	**25 %** **N; R51-53: 2,5 % ≤ C < 25 %** **R52-53: 0,25 % ≤ C < 2,5 %**	
613-318-00-5	**fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate**	**-**	**473798-59-3**	**N; R51-53**	**N** **R: 51/53** **S: 60-61**		
616-212-00-7	**3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate**	**259-627-5**	**55406-53-6**	**T; R23-48/23** **Xn; R22** **Xi; R41** **R43** **N; R50**	**T; N** **R: 22-23-41-43-48/23-50** **S: (1/2-)24-26-37/39-45-63**	**N; R50: C ≥ 2,5 %'**	